Article Text

Download PDFPDF
Infliximab-induced interstitial lung disease
  1. Theodoros Karampitsakos,
  2. Ourania Papaioannou,
  3. Fotios Sampsonas and
  4. Argyrios Tzouvelekis
  1. Department of Respiratory Medicine, University Hospital of Patras, Patras, Greece
  1. Correspondence to Dr Fotios Sampsonas; fsampsonas{at}


A 70-year-old man was referred to our respiratory department with non-productive cough over the past 6 months. High-resolution CT revealed reticular pattern with basal and peripheral predominance, centrilobular nodules and mild ground glass opacities. Serology tests were normal and bronchoalveolar lavage revealed lymphocytosis. Pulmonary function tests showed functional impairment and reduced diffusing capacity for carbon monoxide. Meticulous evaluation of patient’s medical history unveiled longitudinal administration of infliximab due to diagnosis of psoriasis. The working diagnosis of drug-induced interstitial lung disease was proposed following multidisciplinary discussion. Considerable radiological and functional improvement was determined 6 months following infliximab discontinuation without implementation of corticosteroids. To this end, the patient has reported remission of cough and functional improvement.

  • interstitial lung disease
  • drugs: respiratory system
  • biological agents

Statistics from


  • Contributors TK and OP were responsible for planning, conduct, reporting, conception and design, acquisition of data, interpretation of data and writing—review and editing. FS and AT were responsible for conceptualisation, writing—review and editing—supervision and project administration.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.